Process Improvement for Maximized Therapeutic Innovation Outcome

Scott A. Waldman; Andre Terzic

doi:10.1002/cpt.929

Process Improvement for Maximized Therapeutic Innovation Outcome

Scott A. Waldman, Andre Terzic

Cardiovascular Medicine

Research output: Contribution to journal › Editorial › peer-review

5 Scopus citations

Abstract

Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

Original language	English (US)
Pages (from-to)	8-12
Number of pages	5
Journal	Clinical pharmacology and therapeutics
Volume	103
Issue number	1
DOIs	https://doi.org/10.1002/cpt.929
State	Published - Jan 2018

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.929

Cite this

@article{594cbad1d72845a785fc0b773d07302c,

title = "Process Improvement for Maximized Therapeutic Innovation Outcome",

abstract = "Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.",

author = "Waldman, {Scott A.} and Andre Terzic",

note = "Funding Information: S.A.W. is the Samuel M.V. Hamilton Endowed Professor of Thomas Jefferson University. A.T. is Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor at Mayo Clinic. This work was supported by grants from the National Institutes of Health (NIH) (R01CA204881, R01CA206026, P30CA56036), Targeted Diagnostic & Therapeutics, Inc., and Mayo Clinic. Publisher Copyright: {\textcopyright} 2017 ASCPT",

year = "2018",

month = jan,

doi = "10.1002/cpt.929",

language = "English (US)",

volume = "103",

pages = "8--12",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Process Improvement for Maximized Therapeutic Innovation Outcome

AU - Waldman, Scott A.

AU - Terzic, Andre

N1 - Funding Information: S.A.W. is the Samuel M.V. Hamilton Endowed Professor of Thomas Jefferson University. A.T. is Michael S. and Mary Sue Shannon Family Director, Center for Regenerative Medicine, and Marriott Family Professor at Mayo Clinic. This work was supported by grants from the National Institutes of Health (NIH) (R01CA204881, R01CA206026, P30CA56036), Targeted Diagnostic & Therapeutics, Inc., and Mayo Clinic. Publisher Copyright: © 2017 ASCPT

PY - 2018/1

Y1 - 2018/1

N2 - Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

AB - Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next-generation solutions in managing health and disease.

UR - http://www.scopus.com/inward/record.url?scp=85038370302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038370302&partnerID=8YFLogxK

U2 - 10.1002/cpt.929

DO - 10.1002/cpt.929

M3 - Editorial

C2 - 29265398

AN - SCOPUS:85038370302

SN - 0009-9236

VL - 103

SP - 8

EP - 12

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 1

ER -

Process Improvement for Maximized Therapeutic Innovation Outcome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this